Mkt Cap $45M
52-Week Range
Lisata Therapeutics, Inc.
Revenue breakdown: Reportable Segment (100%).
$45M
Market Cap
$176.8K
Revenue
-$17M
Net Income
Revenue by Segment
Entry into a Material Definitive Agreement. Agreement and Plan of Merger On March 6, 2026, Lisata Therapeutics, Inc., a Delaware corporation (the “Company” or “
Entry into a Material Definitive Agreement. Reference is made to the binding term sheet (the “Term Sheet”), dated as of January 20, 2026, by and between Lisata
Entry into a Material Definitive Agreement. Term Sheet On January 20, 2026, Lisata Therapeutics, Inc., a Delaware corporation (the “ Company ” or “ Lisata ”), e
| Other Events | |---|---| On April 2, 2026, Lisata Therapeutics, Inc. (the “Company” or “Lisata”) and Kuva Labs Inc., a Delaware corporation (“Parent”), togeth
Other Events. On January 23, 2026, Lisata Therapeutics, Inc. (the “Company”) and Qilu Pharmaceutical Co., Ltd. (“Qilu”) entered into a Mutual Termination Agreem